Protection and repair of the injured spinal cord: A review of completed, ongoing, and planned clinical trials for acute spinal cord injury

Neurosurgical Focus

Volumn 25, Issue 5, 2008, Pages

  Hawryluk, Gregory W J ^a,b   Rowland, James ^a   Kwon, Brian K ^d   Fehlings, Michael G ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cell replacement therapy; Neuroprotection; Spinal cord injury; Stem cell; Surgical timing; Translational research

Indexed keywords

NEUROPROTECTIVE AGENT;

ANIMAL; DRUG EFFECT; HUMAN; METABOLISM; MYELIN SHEATH; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPINAL CORD INJURY; TREATMENT OUTCOME; WOUND HEALING;

ANIMALS; HUMANS; MYELIN SHEATH; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL CORD INJURIES; TREATMENT OUTCOME; WOUND HEALING;

EID: 63849186608     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/FOC.2008.25.11.E14     Document Type: Article

References (154)

1. AANS/CNS: Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 50:S63-S72, 2002
2. Aito S, D'Andrea M, Werhagen L, Farsetti L, Cappelli S, Bandini B, et al: Neurological and functional outcome in traumatic central cord syndrome. Spinal Cord 45:292-297, 2007
3. Anstett P: We have to overcome this hope barrier. Detriot, MI: Detroit Free Press, June 7, 2005
4. Baptiste DC, Fehlings M: Update on the treatment of spinal cord injury. Prog Brain Res 161:217-233, 2007
5. Baptiste DC, Fehlings MG: Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 23:318-334, 2006
6. Barbeau H, Ladouceur M, Mirbagheri MM, Kearney RE: The effect of locomotor training combined with functional electrical stimulation in chronic spinal cord injured subjects: walking and reflex studies. Brain Res Brain Res Rev 40:274-291, 2002
7. Baskin DS, Simpson RK Jr, Browning JL, Dudley AW, Rothenberg F, Bogue L: The effect of long-term high-dose naloxone infusion in experimental blunt spinal cord injury. J Spinal Disord 6:38-43, 1993
8. Bhatt JM, Gordon PH: Current clinical trials in amyotrophic lateral sclerosis. Expert Opin Investig Drugs 16:1197-1207, 2007
9. Bose B, Osterholm JL, Kalia M: Ganglioside-induced regeneration and reestablishment of axonal continuity in spinal cord-transected rats. Neurosci Lett 63:165-169, 1986
10. Boyd JG, Doucette R, Kawaja MD: Defining the role of olfactory ensheathing cells in facilitating axon remyelination following damage to the spinal cord. FASEB J 19:694-703, 2005
11. Bracken MB: Methylprednisolone and acute spinal cord injury: an update of the randomized evidence. Spine 26:S47-S54, 2001
12. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinalcord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322:1405-1411, 1990
13. Bracken MB, Shepard MJ, Hellenbrand KG, Collins WF, Leo LS, Freeman DF, et al: Methylprednisolone and neurological function 1 year after spinal cord injury: results of the National Acute Spinal Cord Injury Study. J Neurosurg 63:704-713, 1985
14. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al: Administration of methylprednisolone for 24 or 48 hours or tirilizad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277:1597-1604, 1997
15. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al: Methylprednisolone or tirilizad mesylate administration after acute spinal cord injury: 1-year follow-up. J Neurosurg 89:699-706, 1998
16. Braughler JM, Hall ED: Effects of multi-dose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J Neurosurg 61:290-295, 1984
17. Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME: Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 378:498-501, 1995
18. Bunge RP: Schwann cells in central regeneration. Ann N Y Acad Sci 633:229-233, 1991
19. Caroni P, Savio T, Schwab ME: Central nervous system regeneration: oligodendrocytes and myelin as non-permissive substrates for neurite growth. Prog Brain Res 78:363-370, 1988
20. Caroni P, Schwab ME: Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron 1:85-96, 1988
21. Caroni P, Schwab ME: Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol 106:1281-1288, 1988
22. Catz A, Agranov E, Ring H, Tamir A: The spinal cord independence measure (SCIM): sensitivity to functional changes in subgroups of spinal cord lesion patients. Spinal Cord 39:97-100, 2001
23. Catz A, Itzkovich M, Steinberg F, Philo O, Ring H, Ronen J, et al: The Catz-Itzkovich SCIM: a revised version of the Spinal Cord Independence Measure. Disabil Rehabil 23:263-268, 2001
24. Cesaro P: The design of clinical trials for cell transplantation into the central nervous system. NeuroRx 1:492-499, 2004
25. Chang RC, Rota C, Glover RE, Mason RP, Hong JS: A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res 854:224-229, 2000
26. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA, et al: Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 403:434-439, 2000
27. Chen TY, Lee ST, Lui TN, Wong CW, Yeh YS, Tzaan WC, et al: Efficacy of surgical treatment in traumatic central cord syndrome. Surg Neurol 48:435-440, 1997
28. Coleman WP, Benzel D, Cahill DW, Ducker T, Geisler F, Green B, et al: A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies. J Spinal Disord 13:185-199, 2000
29. Coselli JS, Lemaire SA, Köksoy C, Schmittling ZC, Curling PE: Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: results of a randomized clinical trial. J Vasc Surg 35:631-639, 2002
30. David S, Aguayo AJ: Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. Science 214:931-933, 1981
31. Davis SM, Albers GW, Diener HC, Lees KR, Norris J: Termination of acute stroke studies involving selfotel treatment. ASSIST Steering Committed. Lancet 349:32, 1997
32. Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L: Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 22:6570-6577, 2002
33. DeVivo MJ: Causes and costs of spinal cord injury in the United States. Spinal Cord 35:809-813, 1997
34. Dimar JR II, Glassman SD, Raque GH, Zhang YP, Shields CB: The influence of spinal canal narrowing and timing of decompression on neurologic recovery after spinal cord contusion in a rat model. Spine 24:1623-1633, 1999
35. Ditunno JF Jr, Ditunno PL, Gravazi V, Scivoletto G, Bernardi M, Castellano V, et al: Walking index for spinal cord injury (WISCI): an international multicenter validity and reliability study. Spinal Cord 38:234-243, 2000
36. Dittuno PL, Dittuno JF Jr: Walking index for spinal cord injury (WISCI II): scale revision. Spinal Cord 39:654-656, 2001
37. Dobkin BH, Curt A, Guest J: Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 20:5-13, 2006
38. Dubreuil CI, Winton MJ, McKerracher L: Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 162:233- 243, 2003
39. Dumont RJ, Verma S, Okonkwo DO, Hurlbert RJ, Boulos PT, Ellegala DB, et al: Acute spinal cord injury, part II: contemporary pharmacotherapy. Clin Neuropharmacol 24:265-279, 2001
40. Dvorak MF, Fisher CG, Hoekema J, Boyd M, Noonan V, Wing PC, et al: Factors predicting motor recovery and functional outcome after traumatic central cord syndrome: a long-term follow-up. Spine 30:2303-2311, 2005
41. Eck JC, Nachtigall D, Humphreys SC, Hodges SD: Questionnaire survey of spine surgeons on the use of methylprednisolone for acute spinal cord injury. Spine 31:E250-E253, 2006
42. Erecinska M, Thoresen M, Silver IA: Effects of hypothermia on energy metabolism in Mammalian central nervous system. J Cereb Blood Flow Metab 23:513-530, 2003
43. Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, et al: Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 45:190-205, 2007
44. Fehlings MG: Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy. Spine 26:S56-S57, 2001
45. Fehlings MG, Perrin RG: The role and timing of early decompression for cervical spinal cord injury: update with a review of recent clinical evidence. Injury 36:B13-B26, 2005
46. Fehlings MG, Tator CH, Linden RD: The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury. J Neurosurg 71:403-416, 1989
47. Féron F, Perry C, Cochrane J, Licina P, Nowitzke A, Urquhart S, et al: Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 128:2951-2960, 2005
48. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA: Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 97:1314-1326, 2006
49. Flamm ES, Young W, Collins WF, Piepmeier J, Clifton GL, Fischer B: A phase I trial of naloxone treatment in acute spinal cord injury. J Neurosurg 63:390-397, 1985
50. Fouad K, Dietz V, Schwab ME: Improving axonal growth and functional recovery after experimental spinal cord injury by neutralizing myelin associated inhibitors. Brain Res Brain Res Rev 36:204-212, 2001
51. Freund P, Schmidlin E, Wannier T, Bloch J, Mir A, Schwab ME, et al: Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 12:790-792, 2006
52. Freund P, Wannier T, Schmidlin E, Bloch J, Mir A, Schwab ME, et al: Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 502:644-659, 2007
53. Gaviria M, Privat A, d'Arbigny P, Kamenka J, Haton H, Ohanna F: Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats. Brain Res 874:200-209, 2000
54. Geisler FH: GM-1 ganglioside and motor recovery following human spinal cord injury. J Emerg Med 11:49-55, 1993
55. Geisler FH, Coleman WP, Grieco G, Poonian D : The Sygen multicenter acute spinal cord injury study. Spine 26:S87-S98, 2001
56. Geisler FH, Dorsey FC, Coleman WP: Recovery of motor function after spinal-cord injury-a randomized, placebocontrolled trial with GM-1 ganglioside. N Engl J Med 324:1829-1838, 1991
57. Globus MY, Alonso O, Dietrich WD, Busto R, Ginsberg MD: Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia. J Neurochem 65:1704-1711, 1995
58. GrandPré T, Nakamura F, Vartanian T, Strittmatter SM: Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 403:439-444, 2000
59. Guest J, Herrera LP, Qian T: Rapid recovery of segmental neurological function in a tetraplegic patient following transplantation of fetal olfactory bulb-derived cells. Spinal Cord 44:135-142, 2006
60. Hachimi-Idrissi S, Van Hemelrijck A, Michotte A, Smolders I, Sarre S, Ebinger G, et al: Postischemic mild hypothermia reduces neurotransmitter release and astroglial cell proliferation during reperfusion after asphyxial cardiac arrest in rats. Brain Res 1019:217-225, 2004
61. Hadley MN, Walters BC, Grabb PA, Oyesiku NM, Przbylski GJ, Resnick DK, et al: Guidelines for the management of acute cervical spine and spinal cord injuries. Clin Neurosurg 49:407-498, 2002
62. Hall ED: Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell Mol Neurobiol 13:415-432, 1993
63. Hall ED: The neuroprotective pharmacology of methylprednisolone. J Neurosurg 76:13-22, 1992
64. Hall ED, Springer JE: Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 1:80-100, 2004
65. Hansebout RR, Tanner JA, Romero-Sierra C: Current status of spinal cord cooling in the treatment of acute spinal cord injury. Spine 9:508-511, 1984
66. Hashimoto T, Fukuda N: Effect of thyrotropin-releasing hormone on the neurologic impairment in rats with spinal cord injury: treatment starting 24 h and 7 days after injury. Eur J Pharmacol 203:25-32, 1991
67. He Y, Appel S, Le W: Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193, 2001
68. Hinkle L, McCaig CD, Robinson KR: The direction of growth of differentiating neurones and myoblasts from frog embryos in an applied electric field. J Physiol 314:121-135, 1981
69. Hirbec H, Gaviria M, Vignon J: Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. CNS Drug Rev 7:172-198, 2001
70. Hofstetter CP, Holmström NA, Lilja JA, Schweinhardt P, Hao J, Spenger C, et al: Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci 8:346-353, 2005
71. Houle JD, Tessler A: Repair of chronic spinal cord injury. Exp Neurol 182:247-260, 2003
72. Huang ZG, Xue D, Preston E, Karbalai H, Buchan AM: Biphasic opening of the blood-brain barrier following transient focal ischemia: effects of hypothermia. Can J Neurol Sci 26:298-304, 1999
73. Huber AB, Schwab ME: Nogo-A, a potent inhibitor of neurite outgrowth and regeneration. Biol Chem 381:407-419, 2000
74. Hurlbert RJ: Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 93:1-7, 2000
75. Hurlbert RJ: The role of steroids in acute spinal cord injury: an evidence-based analysis. Spine 26:S39-S46, 2001
76. Hurlbert RJ, Moulton R: Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and a position statement. Can J Neurol Sci 29:236-239, 2002
77. Inamasu J, Suga S, Sato S, Horiguchi T, Akaji K, Mayanagi K, et al: Post-ischemic hypothermia delayed neutrophil accumulation and microglial activation following transient focal ischemia in rats. J Neuroimmunol 109:66-74, 2000
78. Ishida Y, Tominaga T: Predictors of neurologic recovery in acute central cervical cord injury with only upper extremity impairment. Spine 27:1652-1658, 2002
79. Jaffe LF, Poo MM: Neurites grow faster towards the cathode than the anode in a steady field. J Exp Zool 209:115-128, 1979
80. Jiang JY, Yang XF: Current status of cerebral protection with mild-to-moderate hypothermia after traumatic brain injury. Curr Opin Crit Care 13:153-155, 2007
81. Karimi-Abdolrezaee S, Eftekharpour E, Wang J, Morshead CM, Fehlings MG: Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci 26:3377- 3389, 2006
82. Keirstead HS, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp K, et al: Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 25:4694-4705, 2005
83. Knoller N, Auerbach G, Fulga V, Zelig G, Attias J, Bakimer R, et al: Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 3:173-181, 2005
84. Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C: Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 330:956-958, 2005
85. Kunihara T, Matsuzaki K, Shiiya N, Saijo Y, Yasuda K: Naloxone lowers cerebrospinal fluid levels of excitatory amino acids after thoracoabdominal aortic surgery. J Vasc Surg 40:681-690, 2004
86. Kwon BK, Mann C, Sohn HM, Hilibrand AS, Phillips FM, Wang JC, et al: Hypothermia for spinal cord injury. Spine J [epub ahead of print], 2008
87. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR: Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 4:451-464, 2004
88. Lallement G, Baubichon D, Clarençon D, Galonnier M, Peoc'h M, Carpentier P: Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military or terrorist attack by soman. Neurotoxicology 20:675-684, 1999
89. Lammertse D, Tuszynski MH, Steeves JD, Curt A, Fawcett JW, Rask C, et al: Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord 45:232-242, 2007
90. Lammertse DP: Update on pharmaceutical trials in acute spinal cord injury. J Spinal Cord Med 27:319-325, 2004
91. Landwehrmeyer GB, Dubois B, de Yébenes JG, Kremer B, Gaus W, Kraus PH, et al: Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 62:262-272, 2007
92. Lebkowski JS, Gold J, Xu C, Funk W, Chiu CP, Carpenter MK: Human embryonic stem cells: culture, differentiation, and genetic modification for regenerative medicine applications. Cancer J 7:83-93, 2001
93. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, et al: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 20:1017-1027, 2003
94. Lei B, Tan X, Cai H, Xu Q, Guo Q: Effect of moderate hypothermia on lipid peroxidation in canine brain tissue after cardiac arrest and resuscitation. Stroke 25:147-152, 1994
95. Lepeintre JF, D'Arbigny P, Mathé JF, Vigué B, Loubert G, Delcour J, et al: Neuroprotective effect of gacyclidine. A multicenter double-blind pilot trial in patients with acute traumatic brain injury. Neurochirurgie 50:83-95, 2004
96. Lima C, Pratas-Vital J, Escada P, Hasse-Ferreira A, Capucho C, Peduzzi JD: Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med 29:191-203, 2006
97. Liu L, Yenari MA: Therapeutic hypothermia: neuroprotective mechanisms. Front Biosci 12:816-825, 2007
98. Long JB, Kinney RC, Malcolm DS, Graeber GM, Holaday JW: Intrathecal dynorphin A1-13 and dynorphin A3-13 reduce rat spinal cord blood flow by non-opioid mechanisms. Brain Res 436:374-379, 1987
99. Lyden P, Wahlgren NG: Mechanisms of action of neuroprotectants in stroke. J Stroke Cerebrovasc Dis 9:9-14, 2000
100. Ma QH, Yang WL, Nie DY, Dawe GS, Xiao ZC: Physiological roles of neurite outgrowth inhibitors in myelinated axons of the central nervous system-implications for the therapeutic neutralization of neurite outgrowth inhibitors. Curr Pharm Des 13:2529-2537, 2007
101. Macias MY, Syring MB, Pizzi MA, Crowe MJ, Alexanian AR, Kurpad SN: Pain with no gain: allodynia following neural stem cell transplantation in spinal cord injury. Exp Neurol 201:335-348, 2006
102. McKerracher L, Higuchi H: Targeting Rho to stimulate repair after spinal cord injury. J Neurotrauma 23:309-317, 2006
103. McKinley W, Meade M, Kirshblum S, Barnard B: Outcomes of early surgical management versus late or no surgical intervention after acute spinal cord injury. Arch Phys Med Rehabil 85:1818-1825, 2004
104. Miller RG, Mitchell JD, Lyon M, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 1:CD001447, 2007
105. Mitha AP, Maynard KI: Gacyclidine (Beaufour-Ipsen). Curr Opin Investig Drugs 2:814-819, 2001
106. Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF: Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J Neurosurg 91:737-743, 1999
107. Mu X, Azbill RD, Springer JE: Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury. J Neurotrauma 17:773-780, 2000
108. Nesathurai S: Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials. J Trauma 45:1088-1093, 1998
109. Nógrádi A, Szabó A, Pintér S, Vrbová G: Delayed riluzole treatment is able to rescue injured rat spinal motoneurons. Neuroscience 144:431-438, 2007
110. Nolan JP, Morley PT, Hoek TL, Hickey RW: Advancement Life support Task Force of the International Liaison committee on Resuscitation: therapeutic hypothermia after cardiac arrest. An advisory statement by the Advancement Life support Task Force of the International Liaison committee on Resuscitation. Resuscitation 57:231-235, 2003
111. Ohmura A, Nakajima W, Ishida A, Yasuoka N, Kawamura M, Miura S, et al: Prolonged hypothermia protects neonatal rat brain against hypoxic-ischemia by reducing both apoptosis and necrosis. Brain Dev 27:517-526, 2005
112. Otani K, Abe H, Kadoya S, Nakagawa H, Ikata T, Tominaga S, et al: Beneficial effects of methylprednisolone sodium succinate in the treatment of acute spinal cord injury. Sekitsy Sekizui 7:633-647, 1994
113. Oudega M, Vargas CG, Weber AB, Kleitman N, Bunge MB: Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur J Neurosci 11:2453-2464, 1999
114. Paralyzed Veterans of America Consortium for Spinal Cord Medicine: Preservation of upper limb function following spinal cord injury: a clinical practice guideline for health-care professionals. J Spinal Cord Med 28:434-470, 2005
115. Park E, Velumian AA, Fehlings MG: The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma 21:754-774, 2004
116. Park HC, Shim YS, Ha Y, Yoon SH, Park SR, Choi BH, et al: Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng 11:913-922, 2005
117. Perry VH, Brown MC, Gordon S: The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J Exp Med 165:1218-1223, 1987
118. Petitjean ME, Pointillart V, Dixmerias F, Wiart L, Sztark F, Lassié P, et al: Medical treatment of spinal cord injury in the acute stage. Ann Fr Anesth Reanim 17:114-122, 1998
119. Pitts LH, Ross A, Chase GA, Faden AI: Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 12:235-243, 1995
120. Pointillart V, Petitjean ME, Wiart L, Vital JM, Lassié P, Thicoipé M, et al: Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 38:71-76, 2000
121. Prinjha R, Moore SE, Vinson M, Blake S, Morrow R, Christie G, et al: Inhibitor of neurite outgrowth in humans. Nature 403:383-384, 2000
122. Qian T, Campagnolo D, Kirshblum S: High-dose methylprednisolone may do more harm for spinal cord injury. Med Hypotheses 55:452-453, 2000
123. Rabinovich SS, Seledtsov VI, Poveschenko OV, Senuykov VV, Taraban VY, Yarochno VI, et al: Transplantation treatment of spinal cord injury patients. Biomed Pharmacother 57:428-433, 2003
124. Ramón-Cueto A, Cordero MI, Santos-Benito FF, Avila J: Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia. Neuron 25:425-435, 2000
125. Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, et al: Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 4:814-821, 1998
126. Richardson PM, McGuinness UM, Aguayo AJ: Axons from CNS neurons regenerate into PNS grafts. Nature 284:264-265, 1980
127. Sagen J: Cellular therapies for spinal cord injury: what will the FDA need to approve moving from the laboratory to the human? J Rehabil Res Dev 40:71-79, 2003
128. Schnell L, Schwab ME: Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 343:269-272, 1990
129. Schwartz G, Fehlings MG: Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 94:245-256, 2001
130. Sekhon LH, Fehlings M: Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 26:S2-S12, 2001
131. Shapiro S, Borgens R, Pascuzzi R, Roos K, Groff M, Purvines S, et al: Oscillating field stimulation for complete spinal cord injury in humans: a phase 1 trial. J Neurosurg Spine 2:3-10, 2005
132. Shortland PJ, Leinster VH, White W, Robson LG: Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. Eur J Neurosci 24:3343-3353, 2006
133. Spillmann AA, Bandtlow CE, Lottspeich F, Keller F, Schwab ME: Identification and characterization of a bovine neurite growth inhibitor (bNI-220). J Biol Chem 273:19283-19293, 1998
134. Steeves JD, Fawcett JW, Tuszynski MH, Lammertse D, Curt A, Ditunno JF, et al: Experimental Treatments for Spinal Cord Injury: What You Should Know if You Are Considering Participation in a Clinical Trial. Vancouver, BC: International Campaign for Cures of Spinal Cord Injury Paralysis, 2007 (http://www.icord.org/ICCP/Experimental_treatment_for_SCIsummary_ nc.pdf) [Accessed 22 September 2008]
135. Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, Ditunno JF, et al: Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 45:206-221, 2007
136. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, et al: Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24:2182- 2190, 2004
137. Syková E, Homola A, Mazanec R, Lachmann H, Konrádová SL, Kobylka P, et al: Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 15:675-687, 2006
138. Tadie M, D'Arbigny P, Mathé J, Loubert G, Saint-Marc C, Menthonnex P, et al: Acute spinal cord injury: early care and treatment in a multicenter study with gacyclidine. Soc Neurosci 25:1090, 1999 (Abstract)
139. Tator CH: Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 59:957-982, 2006
140. Tator CH, Fehlings MG, Thorpe K, Taylor W: Current use and timing of spinal surgery for management of acute spinal surgery for management of acute spinal cord injury in North America: results of a retrospective multicenter study. J Neurosurg 91:12-18, 1999
141. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, et al: Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 101:3071-3076, 2004
142. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166:7527-7533, 2001
143. Tuszynski MH, Steeves JD, Fawcett JW, Lammertse D, Kalichman M, Rask C, et al: Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 45:222-231, 2007
144. van Hedel HJ, Wirz M, Dietz V: Assessing walking ability in subjects with spinal cord injury: validity and reliability of 3 walking tests. Arch Phys Med Rehabil 86:190-196, 2005
145. Vogel G: Cell biology. Ready or not? Human ES cells head toward the clinic. Science 308:1534-1538, 2005
146. Wang SJ, Wang KY, Wang WC: Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125:191-201, 2004
147. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW: Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126:1628-1637, 2003
148. Winkler T, Sharma HS, Stålberg E, Olsson Y, Nyberg F: Naloxone reduces alterations in evoked potentials and edema in trauma to the rat spinal cord. Acta Neurochir Suppl (Wien) 60:511-515, 1994
149. Yamazaki T, Yanaka K, Fujita K, Kamezaki T, Uemura K, Nose T: Traumatic central cord syndrome: analysis of factors affecting the outcome. Surg Neurol 63:95-99, 2005
150. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM: The promise of minocycline in neurology. Lancet Neurol 3:744-751, 2004
151. Yoon SH, Shim YS, Park YH, Chung JK, Nam JH, Kim MO, et al: Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. Stem Cells 25:2066-2073, 2007
152. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95:15769-15774, 1998
153. Yune TY, Lee JY, Jung GY, Kim SJ, Jiang MH, Kim YC, et al: Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 27:7751-7761, 2007
154. Zornow MH: Inhibition of glutamate release: a possible mechanism of hypothermic neuroprotection. J Neurosurg Anesthesiol 7:148-151, 1995